Drug-drug interaction risk assessment using PBPK modeling: inhibitory magnitude of diltiazem and its metabolite on sirolimus disposition

Chie Emoto

[P25-8-10] Drug-drug interaction risk assessment using PBPK modeling: inhibitory magnitude of diltiazem and its metabolite on sirolimus disposition

Chie Emoto¹, Alexander A. Vinks², Tsuyoshi Fukuda³ (1.Cincinnati Children's Hospital Medical Center, 2.Cincinnati Children's Hospital Medical Center, 3.Cincinnati Children's Hospital Medical Center)

Keywords:Drug-drug interaction, Risk assessment, PBPK modeling, Sirolimus, Diltiazem

Abstract password authentication.
Password to view abstracts and 'Participants' page is announced on the e-blast sent to early-bird/advanced registrants on September 13. It is also on the page 7 of IATDMCT 2017 PROGRAM BOOK.

Presentation information

[P25-8] P25-8: Immunosuppressive drugs (3): Biomarkers and pharmacokinetics

[P25-8-10] Drug-drug interaction risk assessment using PBPK modeling: inhibitory magnitude of diltiazem and its metabolite on sirolimus disposition

Password